Table 3 CRBN genotypes versus toxicity grades.
From: Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Hypoalbuminemia Grade | |||||
Genotype | 0 | 1 | 2 | 3 | P (trend) |
n (%) | n (%) | n (%) | n (%) | ||
CRBN rs1672753 | |||||
CC | 1 (33) | 2 (67) | 0 (0) | 0 (0) | 0.0008 |
CT | 2 (20) | 8 (80) | 0 (0) | 0 (0) | |
TT | 1 (4) | 13 (48) | 10 (37) | 3 (11) | |
Hyperbilirubinemia Grade | |||||
0 | 1 | 2 | P (trend) | ||
CRBN rs1714327 | |||||
CC | 3 (18) | 8 (47) | 6 (35) | 0.0010 | |
CG | 11 (65) | 4 (24) | 2 (12) | ||
GG | 6 (75) | 2 (25) | 0 (0) | ||
